UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 53.3%

Neg 0% Neu 0% Pos 53.3%

UBS analyst A.J. Rice maintains Pediatrix Medical Group (NYSE:MD) with a Neutral and raises the price target from $22 to $25.